Literature DB >> 16184615

Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.

Michael J Borowitz1, D Jeanette Pullen, Naomi Winick, Paul L Martin, W Paul Bowman, Bruce Camitta.   

Abstract

BACKGROUND: Flow cytometric analysis of minimal residual disease (MRD) depends on detecting phenotypically abnormal populations. However, little is known about how phenotypic shifts between diagnosis and relapse affect MRD detection in childhood acute lymphoid leukemia (ALL).
METHODS: We compared diagnostic and relapse bone marrow specimens in 42 children with precursor B-ALL studied with the two-tube panel CD19-APC/CD45-PerCP/CD10-PE/CD20-FITC and CD19-APC/CD45-PerCP/CD9-PE/CD34-FITC.
RESULTS: At least 29 cases had phenotypic shifts of intensity or coefficient of variation of distribution of one or more markers. Shifts were complex and could not be explained by change in maturation stage. In the majority of cases MRD populations more closely resembled the diagnostic than the relapse specimen. In 6 of 7 MRD negative cases we did not identify an abnormal population that resembled diagnosis or relapse. In the remaining case, in which CD34 and CD10 were lost between diagnosis and relapse, it is possible that we could have missed an MRD population resembling relapse.
CONCLUSIONS: Phenotypic shifts are common, but do not affect MRD recognition. At most 1 of 42 cases might have harbored an abnormal population undetected because of shift. However, MRD analysis with rigid gating (looking strictly for abnormal phenotypes at diagnosis) might have missed many positive cases, 8 of 22 (36%) in this series. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16184615     DOI: 10.1002/cyto.b.20071

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  15 in total

1.  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Giuseppe Gaipa; Giovanni Cazzaniga; Maria Grazia Valsecchi; Renate Panzer-Grümayer; Barbara Buldini; Daniela Silvestri; Leonid Karawajew; Oscar Maglia; Richard Ratei; Alessandra Benetello; Simona Sala; Angela Schumich; Andre Schrauder; Tiziana Villa; Marinella Veltroni; Wolf-Dieter Ludwig; Valentino Conter; Martin Schrappe; Andrea Biondi; Michael N Dworzak; Giuseppe Basso
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

2.  A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Authors:  Michael Keeney; Brent L Wood; Benjamin D Hedley; Joseph A DiGiuseppe; Maryalice Stetler-Stevenson; Elisabeth Paietta; Gerard Lozanski; Adam C Seegmiller; Bruce W Greig; Aaron C Shaver; Lata Mukundan; Howard R Higley; Caroline C Sigman; Gary Kelloff; J Milburn Jessup; Michael J Borowitz
Journal:  Cytometry B Clin Cytom       Date:  2017-05-05       Impact factor: 3.058

3.  Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.

Authors:  Mikhail Roshal; Jonathan R Fromm; Stuart Winter; Kimberly Dunsmore; Brent L Wood
Journal:  Cytometry B Clin Cytom       Date:  2010-05       Impact factor: 3.058

4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

5.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Authors:  Michael N Dworzak; Angela Schumich; Dieter Printz; Ulrike Pötschger; Zvenyslava Husak; Andishe Attarbaschi; Giuseppe Basso; Giuseppe Gaipa; Richard Ratei; Georg Mann; Helmut Gadner
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

6.  Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.

Authors:  Julie Irving; Jenny Jesson; Paul Virgo; Marian Case; Lynne Minto; Lisa Eyre; Nigel Noel; Ulrika Johansson; Marion Macey; Linda Knotts; Margaret Helliwell; Paul Davies; Liam Whitby; David Barnett; Jeremy Hancock; Nick Goulden; Sarah Lawson
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

7.  Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.

Authors:  Wenbin Xiao; Dalia Salem; Catharine S McCoy; Daniel Lee; Nirali N Shah; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Cytometry B Clin Cytom       Date:  2017-10-31       Impact factor: 3.058

Review 8.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 9.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

10.  Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.

Authors:  K Matlawska-Wasowska; E Ward; S Stevens; Y Wang; R Herbst; S S Winter; B S Wilson
Journal:  Leukemia       Date:  2013-01-11       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.